Ads
related to: latest research on schizophrenia treatment guidelines
Search results
Results from the WOW.Com Content Network
A new first-in-class antipsychotic that targets multiple neurotransmitter systems called lumateperone (ITI-007), was trialed and approved by the FDA in December 2019 for the treatment of schizophrenia in adults. [24] [26] [27] Lumateperone is a small molecule agent that shows improved safety, and tolerance.
The effectiveness of xanomeline/trospium chloride for the treatment of schizophrenia in adults was evaluated in two studies with identical designs. [2] Study 1 (NCT04659161) and study 2 (NCT04738123) were 5-week, randomized, double-blind, placebo-controlled, multi-center studies in adults with a diagnosis of schizophrenia according to DSM-5 ...
Kakar—a psychiatrist who treats patients as well as conducts research—says that historically, only about 40% of people with schizophrenia respond to dopamine-based treatments, and the other 60 ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...
Schizophrenia Bulletin is a peer-reviewed medical journal which covers research relating to the etiology and treatment of schizophrenia. The journal is published bimonthly by Oxford University Press in association with the Maryland Psychiatric Research Center and Schizophrenia International Research Society .
More than 40 percent of all people with schizophrenia end up in supervised group housing, nursing homes or hospitals. Another 6 percent end up in jail, usually for misdemeanors or petty crimes, while an equal proportion end up on the streets. Among researchers, schizophrenia has long been known as the “graveyard of psychiatric research.”
Ads
related to: latest research on schizophrenia treatment guidelines